Merz Therapeutics to present key data on XEOMIN^® (incobotulinumtoxinA) at Toxins 2021 Virtual Conference

• 18 accepted abstract presentations provide important updates and data on XEOMIN
• Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins

RALEIGH, N.C. – January 15, 2021 – Merz Therapeutics announced today the presentation of data from 18 accepted abstracts on XEOMIN^® (incobotulinumtoxinA) at TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place virtually January 16 and 17.

“Merz Therapeutics is excited to virtually present our robust data at the global TOXINS 2021 conference, and share important updates and clinical developments for XEOMIN, including data on its immunogenicity profile from recent clinical trials for our two new pediatric indications in the U.S.,” said Stefan Albrecht, Chief Scientific and Medical Officer, Merz Therapeutics. “Although we’re unable to gather in person for this year’s meeting, we look forward to participating and connecting with our industry peers virtually.”

The following presentations will be shared virtually at the TOXINS meeting and are intended to enhance the exchange of scientific information. All associated abstracts will be published in an online supplemental issue of Toxicon, with open access for six months following the virtual conference.

ORAL & VIDEO ABSTRACT PRESENTATION

• Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of three phase 3 studies, Henry Chambers, Rady Children’s Hospital, San Diego, CA, USA

SCIENTIFIC E-POSTER PRESENTATIONS

• Pooled efficacy analysis of incobotulinumtoxinA in the multipattern treatments of upper-and lower-limb spasticity in children and adolescents with cerebral palsy, Florian Heinen, Ludwig Maximilian University of Munich, Munich, Germany
• Safety of incobotulinumtoxinA in multipattern treatment of upper- and lower-limb spasticity in children/adolescents with cerebral palsy: pooled analysis of three large phase 3 studies,
  Marta Banach, Jagiellonian University Medical College, Krakow, Poland
• Pooled efficacy and safety analysis of incobotulinumtoxinA in the treatment of upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS LEVEL IV & V),
  Petr Kaňovský, Palacký University Olomouc, Olomouc, Czech Republic
• Sustained efficacy of incobotulinumtoxinA over 6 injection cycles for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy, Sebastian Schroeder, Ludwig Maximilian University of Munich, Munich, Germany
• Efficacy of incobotulinumtoxinA in the treatment of 6-17 year old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability,
  Steffen Berweck, Schoen Klinik Vogtareuth, Vogtareuth, Germany
• Safety of incobotulinumtoxinA in the treatment of 6-17 year old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability,
  Steffen Berweck, Schoen Klinik Vogtareuth, Vogtareuth, Germany

• Efficacy and safety of incobotulinumtoxinA in the treatment of 2-5 year old children with chronic sialorrhea associated with neurological disorders and/or intellectual disability, Steffen Berweck, Schoen Klinik Vogtareuth, Vogtareuth, Germany

• Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of three Phase 3 studies, Florian Heinen, Ludwig Maximilian University of Munich, Munich, Germany
• Efficacy and safety of incobotulinumtoxinA in the treatment of lower-limb spasticity in adults: the PATTERN customized study design, Gerard Francisco, University of Texas McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA
• Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children and adolescents with cerebral palsy: results of the phase 3 XARA study, Edward Dabrowski, Beaumont Pediatric Physical Medicine & Rehabilitation, Royal Oak, MI, USA
• Efficacy and safety of incobotulinumtoxina in the treatment of lower-limb spasticity in Japanese patients, Ryuji Kaji, Tokushima University, Tokushima, Japan
• Botulinum toxin overdoses and association with medication errors, Rashid Kazerooni, Merz Pharmaceuticals, LLC
• Decreased therapeutic effect over time amongst botulinum toxin agents, Rashid Kazerooni, Merz Pharmaceuticals, LLC
• Cost-utility analysis of flexible intervals with incobotulinumtoxina versus fixed dosing with onabotulinumtoxina in the management of cervical dystonia and blepharospasm in major Canadian markets, Marie-Eve Gendron, Merz Pharma Canada Ltd.
• Duration of effect of incobotulinumtoxina for the treatment of blepharospasm in botulinum toxin-naïve subjects: results from a phase 3 study, Dimos Mitsikostas, National & Kapodistrian University of Athens, Athens, Greece
• Duration of treatment effect using incobotulinumtoxinA for upper-limb spasticity: a post-hoc analysis, Petr Kaňovský, Palacký University Olomouc, Olomouc, Czech Republic
• Sustained efficacy of incobotulinumtoxinA in upper-limb post-stroke spasticity: a post-hoc analysis, Petr Kaňovský, Palacký University Olomouc, Olomouc, Czech Republic

Presentations will be viewable by attendees in the Virtual Poster Hall for the duration of the meeting beginning on Saturday, January 16. Conference attendees will have access to the virtual conference hall for 60 days post-conference.

Merz Therapeutics

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

XEOMIN^® (incobotulinumtoxinA) IMPORTANT CONSUMER SAFETY INFORMATION


Read the Medication Guide before you start receiving XEOMIN^® (Zeo-min) and each time XEOMIN is given to you as there may be new information.  The risk information provided here is not comprehensive. To learn more:

• Talk to your health care provider or pharmacist
• Visit www.xeomin.com to obtain the FDA-approved product labeling
• Call 1-844-4MYMERZ (1-844-469-6379)

Uses

XEOMIN is a prescription medicine:

• that is injected into glands that make saliva and is used to treat long-lasting (chronic) drooling (sialorrhea) in adults and in children 2 to 17 years of age.
• that is injected into muscles and used to:
  • treat increased muscle stiffness in the arm because of upper limb spasticity in adults.
  • treat increased muscle stiffness in the arm in children 2 to 17 years of age with upper limb spasticity, excluding spasticity caused by cerebral palsy.
  • treat the abnormal head position and neck pain with cervical dystonia (CD) in adults.
  • treat abnormal spasm of the eyelids (blepharospasm) in adults.

It is not known if XEOMIN is safe and effective in children younger than:

• 2 years of age for the treatment of chronic sialorrhea
• 2 years of age for the treatment of upper limb spasticity
• 18 years of age for the treatment of cervical dystonia or blepharospasm

Warnings
XEOMIN may cause serious side effects that can be life threatening.  Get medical help right away if you have any of these problems any time (hours to weeks) after injection of XEOMIN:

• Problems swallowing, speaking, or breathing can happen if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN.
  • People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN.
  • Swallowing problems may last for several months, and during that time you may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving XEOMIN have the highest risk of getting these problems.
• Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include: loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.

These symptoms can happen hours to weeks after you receive an injection of XEOMIN. These problems could make it unsafe for you to drive a car or do other dangerous activities.

Do not take XEOMIN if you: are allergic to XEOMIN or any of the ingredients in XEOMIN (see below for a list of ingredients in XEOMIN), had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (Myobloc^®), onabotulinumtoxinA (Botox^®, Botox^® Cosmetic), or abobotulinumtoxinA (Dysport^®) or have a skin infection at the planned injection site.

Before receiving XEOMIN, tell your doctor about all of your medical conditions, including if you:

• have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome)
• have had any side effect from any other botulinum toxin in the past
• have a breathing problem, such as asthma or emphysema
• have a history of swallowing problems or inhaling food or fluid into your lungs (aspiration)
• have drooping eyelids
• have had eye surgery
• have had surgery on your face
• are pregnant or plan to become pregnant. It is not known if XEOMIN can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if XEOMIN passes into breast milk.

Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Talk to your doctor before you take any new medicines after you receive XEOMIN.

Using XEOMIN with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received XEOMIN in the past.
Especially tell your doctor if you:

• have received any other botulinum toxin product in the last four months
• have received injections of botulinum toxin such as rimabotulinumtoxinB (MYOBLOC^®), onabotulinumtoxinA (BOTOX^®, BOTOX^® COSMETIC) and abobotulinumtoxinA (DYSPORT^®) in the past.  Be sure your doctor knows exactly which product you received. The dose of XEOMIN may be different from other botulinum toxin products that you have received.
• have recently received an antibiotic by injection or inhalation
• take muscle relaxants
• take an allergy or cold medicine
• take a sleep medicine

Ask your doctor if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

Possible Side Effects

XEOMIN can cause serious side effects including:

• Injury to the cornea (the clear front surface of the eye) in people treated for blepharospasm. People who receive XEOMIN to treat spasm of the eyelid may have reduced blinking that can cause a sore on their cornea or other problems of the cornea. Call your healthcare provider or get medical care right away if you have eye pain or irritation after treatment with XEOMIN.
• XEOMIN may cause other serious side effects including allergic reactions. Symptoms of an allergic reaction to XEOMIN may include: itching, rash, redness, swelling, wheezing, trouble breathing, or dizziness or feeling faint.  Tell your doctor or get medical help right away if you get wheezing or trouble breathing, or if you get dizzy or faint.

The most common side effects of XEOMIN in adults with chronic sialorrhea include:

The most common side effects of XEOMIN in children 2 to 17 years of age with chronic sialorrhea include:

The most common side effects of XEOMIN in adults with upper limb spasticity include:

The most common side effects of XEOMIN in children 2 to 17 years of age with upper limb spasticity include:

The most common side effects of XEOMIN in adults with cervical dystonia include:

The most common side effects of XEOMIN in adults with blepharospasm include:

These are not all the possible side effects of XEOMIN.
Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of XEOMIN
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or doctor for information about XEOMIN that is written for health professionals.

Active Ingredient: botulinum toxin type A

Inactive Ingredients: human albumin and sucrose

Copyright © 2021 Merz Pharmaceuticals, LLC. All rights reserved. MERZ, the MERZ logo, and
XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. Botox, Dysport and
Myobloc are registered trademarks of their respective owners.

For more information, please see the XEOMIN full Prescribing Information and Medication Guide at www.xeomin.com.